Pharmaceuticals News and Research

RSS

JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema

KalVista Pharmaceuticals and JDRF have formed a research partnership focused on a novel approach being developed by KalVista to preserve vision and slow the progression of diabetic eye disease.

9 Jan 2012

Shire, ICON sign strategic partnership agreement

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that is has signed a strategic partnership with Shire Specialty Pharmaceuticals to serve as the sole global provider of central laboratory services and one of two strategic partners for clinical development services.

9 Jan 2012

Colby's JVRS-100 enhances immunogenicity, cross-protective efficacy of H5N1 influenza vaccine

Colby Pharmaceutical Company (CPC) today announced publication of new results showing that a single dose of JVRS-100 adjuvanted H5N1 influenza vaccine enhanced-immune responses, -dose sparing, and -cross-clade influenza virus protection.

9 Jan 2012

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with miRagen Therapeutics, Inc., to assess the delivery potential of Silence's proprietary DBTC delivery system with miRagen's novel microRNA-based therapeutics.

9 Jan 2012

Scientists develop simple, reliable test to identify biomarkers for MPS

A team of scientists, led by researchers at the University of California, San Diego School of Medicine and Zacharon Pharmaceuticals, have developed a simple, reliable test for identifying biomarkers for mucopolysaccharidoses (MPS), a group of inherited metabolic disorders that are currently diagnosed in patients only after symptoms have become serious and the damage possibly irreversible.

8 Jan 2012

Positive results from BioCryst's BCX4208 Phase 2b study on gout

BioCryst Pharmaceuticals, Inc. announced long-term results from the extension phase of its randomized Phase 2b study of BCX4208 added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone.

8 Jan 2012

Bristol-Myers Squibb signs definitive agreement to acquire Inhibitex

Bristol-Myers Squibb Company and Inhibitex, Inc. announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger.

8 Jan 2012

Proteomics: Thermo Fisher Scientific and PREMIER Biosoft to co-market SimGlycan software

Thermo Fisher Scientific Inc., the world leader in serving science, and PREMIER Biosoft, have announced an agreement to co-market PREMIER Biosoft’s SimGlycan® software. The agreement aims to advance glycobiology by dramatically speeding the characterization of complex glycans through automated interpretation of the rich data produced by Thermo Scientific mass spectrometer systems.

From Thermo Fisher Scientific Inc. 8 Jan 2012

Georgia Bio announces 2012 Deals of the Year for pharma, biopharma and medical device companies

Georgia Bio announced its 2012 Deals of the Year for pharmaceutical, biopharmaceutical and medical device companies in four categories - public and private financings, fast growing companies, acquisitions and SBIR grants - reflecting a broad range of activity.

From Medtronic 7 Jan 2012

Challenges in new product planning and development process for pharmaceutical industry

The new product planning and development process is fraught with challenges, from regulatory requirements and safety concerns to cost constraints and competitive pressures. New product planning leaders looking to safeguard their new products' success in 2012 and beyond need an updated road map to help guide them through the new clinical development landscape.

7 Jan 2012

Allsup and PRIUM partner to address pharmacy regimens and costs for MSAs

PRIUM and Allsup Medicare Secondary Payer Compliance Services have joined forces to address pharmacy regimens and costs before submitting Medicare Set-Asides to the Centers for Medicare and Medicaid Services.

7 Jan 2012

Questcor reports record vial shipments of Acthar in fourth quarter 2011

In preparation for meetings starting Monday, January 9 with investors and an investor presentation scheduled for 10:00 a.m. Thursday, January 12 at the J. P. Morgan Healthcare Conference, Questcor Pharmaceuticals, Inc. today announced preliminary operating metrics for the fourth quarter 2011.

7 Jan 2012

New Zealand life science and health IT companies to showcase their products in San Francisco

New Zealand is well known for its wines and stunning scenery, but the country is also a great source of innovation in the life sciences. A delegation of New Zealand life sciences companies who have reached key stages in their development are joining the throngs of international therapeutics, medical device and health IT companies in San Francisco, January 9 - 12 to showcase their products and capabilities to potential corporate partners and investors.

7 Jan 2012

New U.S. patent covers key element of Xencor's Xtend half-life prolongation technology

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, announced today that the U.S. Patent and Trademark Office has issued Xencor a broad patent covering optimized monoclonal antibody variants and their application for extending in vivo half-life of antibodies.

7 Jan 2012

Lightlake intends to develop a treatment for premenstrual syndrome overeating

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it intends to develop a treatment for premenstrual syndrome (PMS) overeating using its patented technology involving opioid antagonists.

7 Jan 2012

OneMedForum San Francisco 2012 event to culminate with 'India Forum'

OneMedPlace today announced that its 5th annual "OneMedForum San Francisco 2012" event will culminate with the "India Forum" on the afternoon of January 11, 2012. The forum will examine how Western companies can capitalize in the booming India market.

7 Jan 2012

AnaptysBio enters new strategic alliances for antibody discovery

AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the initiation of new strategic alliances with two partners: Novartis and an undisclosed second pharmaceutical company.

7 Jan 2012

Breckenridge submits Paragraph IV certifications for seven ANDAs

Breckenridge Pharmaceutical, Inc.announced that it has submitted Paragraph IV (PIV) certifications for seven (7) different Abbreviated New Drug Applications (ANDA) during the 2011 calendar year and intends to submit at least five (5) each year for the next several years.

7 Jan 2012

The Tech Group, Pepex partner to develop Trio systems and sensor modules

Pepex Biomedical, Inc., a privately held company that has developed an all new proprietary sensor technology known as "CCM", announced today it has reached an agreement with The Tech Group , a division of West Pharmaceuticals Services, Inc., to be the premier manufacturer of the Trio systems and sensor modules.

7 Jan 2012

PCI Biotech focuses on localised cancer therapy with minimum side effects

Side effects are currently the biggest problem with any cancer treatment. A Norwegian biotech company is drawing closer to the goal of creating a treatment which kills only cancer cells, leaving other cells unaffected.

7 Jan 2012

Pharmaceuticals News and Research

JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema

Shire, ICON sign strategic partnership agreement

Colby's JVRS-100 enhances immunogenicity, cross-protective efficacy of H5N1 influenza vaccine

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

Scientists develop simple, reliable test to identify biomarkers for MPS

Positive results from BioCryst's BCX4208 Phase 2b study on gout

Bristol-Myers Squibb signs definitive agreement to acquire Inhibitex

Proteomics: Thermo Fisher Scientific and PREMIER Biosoft to co-market SimGlycan software

Georgia Bio announces 2012 Deals of the Year for pharma, biopharma and medical device companies

Challenges in new product planning and development process for pharmaceutical industry

Allsup and PRIUM partner to address pharmacy regimens and costs for MSAs

Questcor reports record vial shipments of Acthar in fourth quarter 2011

New Zealand life science and health IT companies to showcase their products in San Francisco

New U.S. patent covers key element of Xencor's Xtend half-life prolongation technology

Lightlake intends to develop a treatment for premenstrual syndrome overeating

OneMedForum San Francisco 2012 event to culminate with 'India Forum'

AnaptysBio enters new strategic alliances for antibody discovery

Breckenridge submits Paragraph IV certifications for seven ANDAs

The Tech Group, Pepex partner to develop Trio systems and sensor modules

PCI Biotech focuses on localised cancer therapy with minimum side effects

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence